ACARBOSE: A NEW OPTION IN THE TREATMENT OF ULCERATIVE COLITIS BY INCREASING HYDROGEN PRODUCTION

Authors

  • De-Qing Zhang
  • Jian-Hong Zhu
  • Wei-Chang Chen

Keywords:

acarbose, ulcerative colitis, hydrogen

Abstract

Acarbose,which is clinically widely used to treat Type 2 Diabetes,is thought to act at the small intestine by competitively inhibiting enzymes that delay the release of glucose from complex carbohydrates, thereby specifically reducing post prandial glucose excursion. The major side-effect of treatment with acarbose, flatulence, occurs when undigested carbohydrates are fermented by colonic bacteria, resulting in considerable amount of hydrogen. We propose that enteric benefits of acarbose is partly attributable to be their ability to neutralise oxidative stress via increased production of H2 in the gastrointestinal tract. Therefore, symptoms of ulcerative colitis in human beings can be ameliorated by acarbose.

Author Biography

De-Qing Zhang

Department of Digestion Internal Medicine, the First Affiliated Hospital ,Soochow University,Su Zhou.

Downloads

How to Cite

Zhang, D.-Q., Zhu, J.-H., & Chen, W.-C. (2012). ACARBOSE: A NEW OPTION IN THE TREATMENT OF ULCERATIVE COLITIS BY INCREASING HYDROGEN PRODUCTION. African Journal of Traditional, Complementary and Alternative Medicines, 10(1), 166–169. Retrieved from https://journals.athmsi.org/index.php/ajtcam/article/view/1668

Issue

Section

Research Papers